AU2020311441B2 - Multi-agent ocular formulations and treatment methods - Google Patents

Multi-agent ocular formulations and treatment methods

Info

Publication number
AU2020311441B2
AU2020311441B2 AU2020311441A AU2020311441A AU2020311441B2 AU 2020311441 B2 AU2020311441 B2 AU 2020311441B2 AU 2020311441 A AU2020311441 A AU 2020311441A AU 2020311441 A AU2020311441 A AU 2020311441A AU 2020311441 B2 AU2020311441 B2 AU 2020311441B2
Authority
AU
Australia
Prior art keywords
copper
composition
agent
therapeutic agent
secondary therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020311441A
Other languages
English (en)
Other versions
AU2020311441A1 (en
Inventor
Balamurali K. Ambati
Randon Michael BURR
Sarah A. MOLOKHIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2020311441A1 publication Critical patent/AU2020311441A1/en
Application granted granted Critical
Publication of AU2020311441B2 publication Critical patent/AU2020311441B2/en
Priority to AU2026201640A priority Critical patent/AU2026201640A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2020311441A 2019-07-11 2020-07-13 Multi-agent ocular formulations and treatment methods Active AU2020311441B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201640A AU2026201640A1 (en) 2019-07-11 2026-03-04 Multi-agent ocular formulations and treatment methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873121P 2019-07-11 2019-07-11
US62/873,121 2019-07-11
PCT/US2020/041837 WO2021007578A1 (en) 2019-07-11 2020-07-13 Multi-agent ocular formulations and treatment methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201640A Division AU2026201640A1 (en) 2019-07-11 2026-03-04 Multi-agent ocular formulations and treatment methods

Publications (2)

Publication Number Publication Date
AU2020311441A1 AU2020311441A1 (en) 2022-02-03
AU2020311441B2 true AU2020311441B2 (en) 2025-12-04

Family

ID=74115334

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020311441A Active AU2020311441B2 (en) 2019-07-11 2020-07-13 Multi-agent ocular formulations and treatment methods
AU2026201640A Pending AU2026201640A1 (en) 2019-07-11 2026-03-04 Multi-agent ocular formulations and treatment methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201640A Pending AU2026201640A1 (en) 2019-07-11 2026-03-04 Multi-agent ocular formulations and treatment methods

Country Status (8)

Country Link
US (1) US20220288114A1 (https=)
EP (1) EP3996644A4 (https=)
JP (1) JP2022541152A (https=)
KR (1) KR20220125210A (https=)
CN (1) CN114364355A (https=)
AU (2) AU2020311441B2 (https=)
CA (1) CA3146848A1 (https=)
WO (1) WO2021007578A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205774B2 (en) * 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
CN114225016B (zh) * 2021-12-02 2024-07-09 北京大学第一医院 一种用于抑制近视及圆锥角膜进展的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450080A1 (en) * 1989-09-27 1991-10-09 Moskovsky Nauchno-Issledovatelsky Institut Glaznykh Boleznei Imeni Gelmgolsta Composition for the treatment of progressive myopia
WO2002096418A1 (en) * 2001-05-25 2002-12-05 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7488898A (en) * 1997-05-16 1998-12-08 Corrective Vision, Inc. Improved contact lens
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US10010502B2 (en) * 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
AU2019205774B2 (en) * 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450080A1 (en) * 1989-09-27 1991-10-09 Moskovsky Nauchno-Issledovatelsky Institut Glaznykh Boleznei Imeni Gelmgolsta Composition for the treatment of progressive myopia
WO2002096418A1 (en) * 2001-05-25 2002-12-05 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARAH MOLOKHIA ET AL: "IVMED-85 eye drops for myopia control in guinea pigs", vol. 60, no. 9 (2019-05-02), page 5896, *

Also Published As

Publication number Publication date
CA3146848A1 (en) 2021-01-14
CN114364355A (zh) 2022-04-15
US20220288114A1 (en) 2022-09-15
AU2026201640A1 (en) 2026-03-26
WO2021007578A1 (en) 2021-01-14
EP3996644A1 (en) 2022-05-18
KR20220125210A (ko) 2022-09-14
AU2020311441A1 (en) 2022-02-03
EP3996644A4 (en) 2023-07-26
JP2022541152A (ja) 2022-09-22

Similar Documents

Publication Publication Date Title
AU2023202236B2 (en) Cross-linking agents and associated methods
US12544400B2 (en) Treatment of myopic progression
AU2026201640A1 (en) Multi-agent ocular formulations and treatment methods
US20240122974A1 (en) Treatment of myopia
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)